每天一个苹果就能让帕金森病医生远离吗
文章讨论美国FDA对Rune Labs Kinematics System的510(k)许可,该系统为基于智能手表的动态监测系统,可远程追踪帕金森病患者的震颤和运动障碍。作者指出该许可表明该数字方法在日常实践中使用安全,与临床测量有可接受的相关性,但对临床医生的即时意义有限,且需更多验证研究才能作为临床试验的主要或次要终点。
要点
- FDA已授予Rune Labs Kinematics System 510(k)许可,用于远程追踪帕金森病患者的震颤和运动障碍。
- 该许可意味着该数字方法在日常实践中可被视为安全使用,与临床测量有可接受的相关性。
- 对临床医生的即时意义有限,因尚需证明数字信号在患者层面与临床有意义结局的相关性。
核心结论
- 该FDA许可表明该数字方法在日常实践中可被视为安全使用,与临床测量有可接受的相关性,但对临床医生的即时意义有限,且对研究的影响目前也受限。
研究设计与样本
- 本文为针对FDA 510(k)许可Rune Labs Kinematics System的评论文章,未报告研究设计与样本。
主要发现
- FDA已授予Rune Labs Kinematics System 510(k)许可,该系统为基于智能手表的动态监测系统,可远程追踪帕金森病患者的震颤和运动障碍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 尚需证明数字信号在患者层面与临床有意义结局的相关性。
- 在可作为一种新的数字方法用于临床试验的主要或次要终点之前,需要更多验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is challenging to reliably assess the motor features of Parkinson's disease in real-time. This has motivated the search for new digital outcomes that can objectively and remotely measure the severity of parkinsonian motor impairments over an extended period of time. The United States Food and Drug Administration (FDA) has recently granted a 510(k) clearance to the Rune Labs Kinematics System, an ambulatory, smartwatch-based monitoring system to remotely track tremor and dyskinesias in persons with Parkinson's disease. The FDA clearance means that this new digital approach can be regarded as being safe for use in daily practice, with acceptable correlations to clinically based measures. However, the immediate implications for clinicians are limited, because it remains to be demonstrated whether the digital signals correlate well to clinically meaningful outcomes at patient level. The impact on research is also restricted for now, as more validation studies are needed before this new digital approach can be used as primary or secondary endpoint in clinical trials. ANN NEUROL 2023;93:681-685.
引用
- Bloem BR, Post E, Hall DA, et al. An Apple a Day to Keep the Parkinson's Disease Doctor Away? Ann Neurol. 2023. PMID: 36708048. doi:10.1002/ana.26612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。